Hal Bar­ron’s swan song at GSK: An ‘ex­cep­tion­al’ lega­cy, thoughts on risk and a sin­gu­lar de­ci­sion-mak­ing mod­el

With boom­ing Shin­grix sales fill­ing its fi­nan­cial sails in the wake of the Ha­le­on spin­out, the ex­ec­u­tive team at New GSK re­peat­ed­ly tout­ed the block­buster op­por­tu­ni­ty pre­sent­ed by their RSV vac­cine dur­ing Q2 calls Wednes­day, promis­ing that the best is yet to come as they upped their guid­ance for the sec­ond half while rais­ing the prospect of more M&A.

“We are de­liv­er­ing,” CEO Em­ma Walm­s­ley told an­a­lysts, with com­mer­cial mo­men­tum, pipeline ad­vances and re­cent late-stage BD moves that are like­ly to be repli­cat­ed be­fore the year is out now that they have more flex­i­bil­i­ty af­ter the Ha­le­on spin­out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER